192 related articles for article (PubMed ID: 12574175)
1. Impairment of myocardial protection in type 2 diabetic patients.
Lee TM; Chou TF
J Clin Endocrinol Metab; 2003 Feb; 88(2):531-7. PubMed ID: 12574175
[TBL] [Abstract][Full Text] [Related]
2. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty.
Lee TM; Su SF; Chou TF; Lee YT; Tsai CH
Circulation; 2002 Jan; 105(3):334-40. PubMed ID: 11804989
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic preconditioning of estrogen by activation of the myocardial adenosine triphosphate-sensitive potassium channel in patients undergoing coronary angioplasty.
Lee TM; Su SF; Chou TF; Tsai CH
J Am Coll Cardiol; 2002 Mar; 39(5):871-7. PubMed ID: 11869855
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of conventional sulfonylureas and glimepiride.
Geisen K; Végh A; Krause E; Papp JG
Horm Metab Res; 1996 Sep; 28(9):496-507. PubMed ID: 8911987
[TBL] [Abstract][Full Text] [Related]
5. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits.
Nieszner E; Posa I; Kocsis E; Pogátsa G; Préda I; Koltai MZ
Exp Clin Endocrinol Diabetes; 2002 Aug; 110(5):212-8. PubMed ID: 12148084
[TBL] [Abstract][Full Text] [Related]
6. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.
Klepzig H; Kober G; Matter C; Luus H; Schneider H; Boedeker KH; Kiowski W; Amann FW; Gruber D; Harris S; Burger W
Eur Heart J; 1999 Mar; 20(6):439-46. PubMed ID: 10213347
[TBL] [Abstract][Full Text] [Related]
7. The role of ATP-sensitive potassium channel blockers in ischemia-reperfusion-induced renal injury versus their effects on cardiac ischemia reperfusion in rats.
Tawfik MK; Abo-Elmatty DM; Ahmed AA
Eur Rev Med Pharmacol Sci; 2009; 13(2):81-93. PubMed ID: 19499842
[TBL] [Abstract][Full Text] [Related]
8. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.
Tomai F; Crea F; Gaspardone A; Versaci F; De Paulis R; Penta de Peppo A; Chiariello L; Gioffrè PA
Circulation; 1994 Aug; 90(2):700-5. PubMed ID: 8044938
[TBL] [Abstract][Full Text] [Related]
9. [Sulphonylurea derivatives and the cardiovascular system].
Filipiak KJ
Przegl Lek; 2000; 57 Suppl 4():19-22. PubMed ID: 11293225
[TBL] [Abstract][Full Text] [Related]
10. Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris.
Ovünç K
Clin Cardiol; 2000 Jul; 23(7):535-9. PubMed ID: 10894443
[TBL] [Abstract][Full Text] [Related]
11. Effect of ischaemic preconditioning on regional release of inflammatory markers.
Lee TM; Lin MS; Tsai CH; Chang NC
Clin Sci (Lond); 2005 Sep; 109(3):267-76. PubMed ID: 15901241
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
[TBL] [Abstract][Full Text] [Related]
13. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
Juurlink DN; Gomes T; Shah BR; Mamdani MM
Diabet Med; 2012 Dec; 29(12):1524-8. PubMed ID: 22913620
[TBL] [Abstract][Full Text] [Related]
14. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
Massi-Benedetti M; Herz M; Pfeiffer C
Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
[TBL] [Abstract][Full Text] [Related]
15. Differential role of K(ATP) channels activated by conjugated estrogens in the regulation of myocardial and coronary protective effects.
Lee TM; Chou TF; Tsai CH
Circulation; 2003 Jan; 107(1):49-54. PubMed ID: 12515742
[TBL] [Abstract][Full Text] [Related]
16. Nicorandil, a hybrid between nitrate and ATP-sensitive potassium channel opener, preconditions human heart to ischemia during percutaneous transluminal coronary angioplasty.
Yasuda T; Hashimura K; Matsu-ura Y; Kato Y; Ueda T; Mori I; Kijima Y
Jpn Circ J; 2001 Jun; 65(6):526-30. PubMed ID: 11407735
[TBL] [Abstract][Full Text] [Related]
17. Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
Spallarossa P; Schiavo M; Rossettin P; Cordone S; Olivotti L; Cordera R; Brunelli C
Diabetes Care; 2001 Apr; 24(4):738-42. PubMed ID: 11315840
[TBL] [Abstract][Full Text] [Related]
18. Haemodynamic and metabolic effects of low daily dose sulphonylureas in diabetic dog hearts.
Pósa I; Kocsis E; Nieszner E; Pogátsa G; Koltai MZ
Arzneimittelforschung; 2002; 52(7):552-9. PubMed ID: 12189779
[TBL] [Abstract][Full Text] [Related]
19. Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
Abbink EJ; Pickkers P; Jansen van Rosendaal A; Lutterman JA; Tack CJ; Russel FG; Smits P
Diabet Med; 2002 Feb; 19(2):136-43. PubMed ID: 11874430
[TBL] [Abstract][Full Text] [Related]
20. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
